BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Opevesostat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Opevesostat\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06979596-11235@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271104
DTEND;VALUE=DATE:20271105
SUMMARY:Opevesostat: Phase 2 readout est. (NCT06979596)
DESCRIPTION:Opevesostat\, phase 2.\nStudy: A Study of MK-5684 in People Wit
 h Certain Solid Tumors (MK-5684-015/OMAHA-015)\nEstimated primary completi
 on: 4 November 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 opevesostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06979596
URL:https://assetmemo.bio/drug/opevesostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136650-11235@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280510
DTEND;VALUE=DATE:20280511
SUMMARY:Opevesostat: Phase 3 readout est. (NCT06136650)
DESCRIPTION:Opevesostat\, phase 3\, Metastatic Castration-Resistant Prostat
 e Cancer.\nStudy: A Study of Opevesostat (MK-5684) Versus Alternative Next
 -generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prosta
 te Cancer (mCRPC) Post One NHA (MK-5684-004)\nEstimated primary completion
 : 10 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/opeves
 ostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06136650
URL:https://assetmemo.bio/drug/opevesostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136624-11235@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Opevesostat: Phase 3 readout est. (NCT06136624)
DESCRIPTION:Opevesostat\, phase 3.\nStudy: Study of Opevesostat (MK-5684) V
 ersus Alternative NHA in mCRPC (MK-5684-003)\nEstimated primary completion
 : 30 November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 pevesostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06136624
URL:https://assetmemo.bio/drug/opevesostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353386-11235@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Opevesostat: Phase 1/2 readout est. (NCT06353386)
DESCRIPTION:Opevesostat\, phase 1/2\, Metastatic Castration-Resistant Prost
 ate Cancer.\nStudy: Substudy 01A: Safety and Efficacy of Opevesostat (MK-5
 684)-Based Treatment Combinations or Opevesostat Alone in Participants Wit
 h Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)\nE
 stimated primary completion: 15 January 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/opevesostat#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06353386
URL:https://assetmemo.bio/drug/opevesostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863272-11235@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20311001
DTEND;VALUE=DATE:20311002
SUMMARY:Opevesostat: Phase 1/2 readout est. (NCT06863272)
DESCRIPTION:Opevesostat\, phase 1/2.\nStudy: A Clinical Study of Ifinatamab
  Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metast
 atic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prosta
 te02)\nEstimated primary completion: 1 October 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/opevesostat#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06863272
URL:https://assetmemo.bio/drug/opevesostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908524-11235@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20320629
DTEND;VALUE=DATE:20320630
SUMMARY:Opevesostat: Phase 1/2 readout est. (NCT07908524)
DESCRIPTION:Opevesostat\, phase 1/2\, Metastatic Castration-Resistant Prost
 ate Cancer.\nStudy: MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzuma
 b Tirumotecan to Treat Prostate Cancer (MK-2870-01A)\nEstimated primary co
 mpletion: 29 June 2032. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/opevesostat#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07908524
URL:https://assetmemo.bio/drug/opevesostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
